Eli Lilly Stock Surges on Demand for Weight-Loss Drugs
Eli Lilly beat earnings expectations for the first quarter and raised its outlook for the year.
Eli Lilly (LLY) stock is rallying more than 5% in Thursday's session after the pharmaceutical giant reported strong first-quarter earnings results and raised its full-year outlook.
In the three months ended March 31, Eli Lilly's revenue increased 26% from the year-ago period to $8.8 billion. Earnings per share (EPS) surged 59.3% to $2.58.
"Lilly's first-quarter performance reflects solid year-over-year revenue growth with strong sales of [weight-loss drugs] Mounjaro and Zepbound," Eli Lilly CEO David A. Ricks said in a statement. "Our progress in addressing some of the world's most significant healthcare challenges has resulted in increased demand for our medicines."
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
The Q1 results were mixed compared with analysts' expectations, which called for revenue of $8.9 billion and EPS of $2.46, according to Yahoo Finance.
Still, Eli Lilly's weaker-than-expected revenue was quickly overlooked after the company increased its full-year outlook. The drugmaker now expects full-year revenue in the range of $42.4 billion to $43.6 billion and earnings to arrive between $13.50 to $14.00 per share. This is up from LLY's previous outlook for revenue in the range of $40.4 billion to $41.6 billion and earnings of $12.20 to $12.70 per share.
"As we continue to make pipeline investments that position us for future growth, we are rapidly expanding manufacturing capacity to make our incretin medicines available to more patients," Ricks said.
Where does Eli Lilly stock stand with analysts?
Analysts were already bullish on the healthcare stock ahead of earnings. According to S&P Global Market Intelligence, the consensus analyst target price for LLY shares is $813.32, representing an upside of just over 5% to current levels. Meanwhile, the consensus recommendation is a Buy.
However, Damien Conover, director of equity strategy at Morningstar, believes Eli Lilly stock was running a little hot ahead of earnings.
"With its 2-star rating, we believe Eli Lilly's stock is overvalued compared with our long-term fair value estimate of $500," Conover said. The $500 estimate represents a downside of more than 35% to current levels.
Related Content
-
The 'Yes, And...' Rule for RetirementRetirement rarely follows the script. That’s why the best retirees learn to improvise.
-
Inheriting Wealth: 4 Mistakes That Could Cost You EverythingGen X and Millennials are expected to receive trillions of dollars in inheritance. Unless it's managed properly, the money could slip through their fingers.
-
'The Money Prism' Solves Retirement Money's Biggest HeadacheThis simple, three-zone system (Blue for bills, Green for paycheck, Red for growth) helps you organize your retirement savings by purpose and time.
-
What Not to Do After Inheriting Wealth: 4 Mistakes That Could Cost You Everything
Gen X and Millennials are expected to receive trillions of dollars in inheritance. Unless it's managed properly, the money could slip through their fingers.
-
'The Money Prism' Solves Retirement Money's Biggest Headache: Here's How
This simple, three-zone system (Blue for bills, Green for paycheck, Red for growth) helps you organize your retirement savings by purpose and time.
-
No, AI Can't Plan Your Retirement: This (Human) Investment Adviser Explains WhyAI has infinite uses. But creating an accurate retirement strategy based on your unique goals is one place where its possibilities seem lacking.
-
A Value Focus Clips Returns for This Mairs & Power Growth FundRough years for UnitedHealth and Fiserv have weighed on returns for one of our favorite mutual funds.
-
Small-Cap Stocks Gain Momentum. That's Good News for This iShares ETFThe clouds appear to be parting for small-cap stocks, which bodes well for one of our favorite exchange-traded funds.
-
Don't Let a 60/40 Portfolio Derail Your Retirement: Why a Cookie-Cutter Approach Could Cost YouChoosing a personalized retirement investment plan, rather than relying on the 60/40 portfolio, could help protect your savings and ensure long-term growth.
-
Are You Winging Your Retirement Plan? A Wealth Adviser's Tips to Help Build Wealth and Navigate RiskIf you have no strategy tying together your accounts or haven't modeled scenarios to make sure your savings will last, then your plan is probably inefficient.
-
Divide and Conquer: Your Annual Financial Plan Made Easy, Courtesy of a Financial AdviserOverwhelmed by your financial to-do list? Split it into four quarters and assign each one goals that connect to the time of year. It could be life-changing.
